ABSTRACT
OBJECTIVE: The peroxisome proliferator-activated receptor-γ coactivator-1α1 (PGC-1α1) regulates genes involved in energy metabolism. Increasing adipose tissue energy expenditure through PGC-1α1 activation is potentially beneficial for systemic metabolism. Pharmacological PGC-1α1 activators could be valuable tools in the fight against obesity and metabolic disease. Finding such compounds has been challenging partly because PGC-1α1 is a transcriptional coactivator with no known ligand-binding properties. While, PGC-1α1 activation is regulated by several mechanisms, protein stabilization is a crucial limiting step due to its short half-life under unstimulated conditions. METHODS: We designed a cell-based high-throughput screening system to identify PGC-1α1 protein stabilizers. Positive hits were tested for their ability to induce endogenous PGC-1α1 protein accumulation and activate target gene expression in brown adipocytes. Select compounds were analyzed for their effects on global gene expression and cellular respiration in adipocytes. RESULTS: Among 7,040 compounds screened, we highlight four small molecules with high activity as measured by: PGC-1α1 protein accumulation, target gene expression, and uncoupled mitochondrial respiration in brown adipocytes. CONCLUSIONS: We identify compounds that induce PGC-1α1 protein accumulation and show that this increases uncoupled respiration in brown adipocytes. This screening platform establishes the foundation for a new class of therapeutics with potential use in obesity and associated disorders.
Subject(s)
Adipocytes, Brown/drug effects , Anti-Obesity Agents/pharmacology , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , Small Molecule Libraries/pharmacology , Uncoupling Agents/pharmacology , Uncoupling Protein 1/metabolism , Adipocytes, Brown/metabolism , Animals , Anti-Obesity Agents/chemistry , Cell Respiration , HEK293 Cells , Humans , Mice , Mitochondria/drug effects , Mitochondria/metabolism , Protein Stability , Small Molecule Libraries/chemistry , Uncoupling Agents/chemistry , Uncoupling Protein 1/geneticsABSTRACT
The peroxisome proliferator-activated receptor gamma (PPARγ) regulates osteoblast and osteoclast differentiation, and is the molecular target of thiazolidinediones (TZDs), insulin sensitizers that enhance glucose utilization and adipocyte differentiation. However, clinical use of TZDs has been limited by side effects including a higher risk of fractures and bone loss. Here we demonstrate that the same post-translational modifications at S112 and S273, which influence PPARγ pro-adipocytic and insulin sensitizing activities, also determine PPARγ osteoblastic (pS112) and osteoclastic (pS273) activities. Treatment of either hyperglycemic or normoglycemic animals with SR10171, an inverse agonist that blocks pS273 but not pS112, increased trabecular and cortical bone while normalizing metabolic parameters. Additionally, SR10171 treatment modulated osteocyte, osteoblast, and osteoclast activities, and decreased marrow adiposity. These data demonstrate that regulation of bone mass and energy metabolism shares similar mechanisms suggesting that one pharmacologic agent could be developed to treat both diabetes and metabolic bone disease.
Subject(s)
Bone Resorption , Osteogenesis , PPAR gamma/metabolism , Protein Processing, Post-Translational , Adipocytes/metabolism , Animals , Bone Resorption/diagnostic imaging , Bone Resorption/metabolism , Bone and Bones/diagnostic imaging , Bone and Bones/metabolism , Cell Line , Energy Metabolism/drug effects , Male , Mice , Models, Animal , Mutation , Osteoblasts/metabolism , Osteoclasts/metabolism , Osteocytes/metabolism , Osteogenesis/drug effects , PPAR alpha/metabolism , PPAR gamma/agonists , PPAR gamma/genetics , Protein Processing, Post-Translational/drug effects , Rosiglitazone , Thiazolidinediones/pharmacology , X-Ray MicrotomographyABSTRACT
Directed screening of a carboxylic acid-containing combinatorial library led to the discovery of potent inhibitors of the integrin VLA-4. Subsequent optimization by solid-phase synthesis afforded a series of sulfonylated dipeptide inhibitors with structural components that when combined in a single hybrid molecule gave a sub-nanomolar inhibitor as a lead for medicinal chemistry. Preliminary metabolic studies led to the discovery of substituted biphenyl derivatives with low picomolar activities. SAR and pharmacokinetic characterization of this series are presented.
Subject(s)
Dipeptides/pharmacology , Integrins/antagonists & inhibitors , Receptors, Lymphocyte Homing/antagonists & inhibitors , Sulfonic Acids/chemistry , Animals , Biological Availability , Dipeptides/chemistry , Dipeptides/pharmacokinetics , Dogs , Integrin alpha4beta1 , Integrins/metabolism , Macaca mulatta , Metabolic Clearance Rate , Rats , Receptors, Lymphocyte Homing/metabolism , Structure-Activity RelationshipABSTRACT
A total synthesis of a structure proposed for himastatin was accomplished. The non-identity of the fully synthetic material with himastatin necessitated a revision of the assigned structure. Confirmation of the revised stereostructure was subsequently confirmed through total synthesis. Among the achievements during this effort were i) stereospecific routes to both anti-cis and syn-cis pyrrolindoline substructures; ii) a practical synthesis to 5-hydroxypiperazic acid in enantiomerically pure form; iii) a Stille coupling leading to a complex bi-indole moiety, and iv) efficient protecting group management throughout the evolving depsipeptide domain. The outlines for a biological pharmacophore have been delineated. The alternating D- and L-substituents in the 6-mer as well as the biaryl linkage connecting the two identical subunits are critical for maintaining biological activity. This pattern is simulated in another antibiotic, and suggests a possible structural trend for future SAR investigations.
